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Introduction 
Numerous studies have demonstrated a clear causal relationship between human papillomavirus 
(HPV) and cervical cancer, with HPV considered necessary but not sufficient to cause cervical 
cancer [1-7]. HPV also plays a causative role in vaginal, anal, head, and neck cancers [2,8-10]. 
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HPV includes over 100 subtypes and is divided into high- and low-risk groups according to 
oncogenic risk. In 2006, a quadrivalent vaccine (Gardasil®, Merck) offering protection against 
high-risk types 16 and 18, and low-risk types 6 and 11, was approved by the Food and Drug 
Administration (FDA). Additionally, a bivalent vaccine (Cervarix®, GlaxoSmithKline) 
protecting against high-risk types 16 and 18, was approved in 2009 [11]. Both vaccines have 
shown close to 100% efficacy against HPV types 16 and 18, the cause of 70% of all cervical 
cancers [12]. In June 2006, the Advisory Committee on Immunization Practices (ACIP) 
recommended vaccination for females 9 to 26 years old [13]. It is hypothesized that with good 
vaccination coverage, the prevalence of HPV and HPV-associated cancers will decline [14]. 
Although comprehensive surveillance for genital HPV positivity and prevalence data are 
considered difficult to estimate, several approximations exist [15]. A 2007 report showed that the 
overall prevalence in the United States of any HPV infection prior to vaccine introduction (2003-
2004) was approximately 27% [16]. A follow-up study published in 2013 showed the overall rate 
from 2007-2010 was 40% [17]. Both of these studies estimate national level prevalence, but were 
conducted on limited sample sizes (less than 5000 per time period), and had conflicting rates, 
with the 2013 study reporting a prevalence during the years 2003-2006 of 43% [17]. Additional 
prevalence estimates exist, but these are often targeted at specific populations, lack sufficient 
sample size, are geographically isolated and often non-U.S. based [18-24]. Therefore, a need 
exists for surveillance with complete U.S. coverage to establish overall positivity and prevalence 
rates as well as trends in these rates [12,25]. 
The goal of this study is to estimate the positivity of high-risk HPV in the United States from 
2004 to 2013 using retrospective data from HPV testing conducted at a national reference 
laboratory. These positivity rates and trends over time should reflect underlying prevalence rates 
in the population of women who undergo regular gynecological testing and should be useful in 
supplementing other nationwide estimates of HPV vaccine impact. 
This study will illustrate that using such data can overcome the limitations of previous studies 
because the number of unique patients tested is large and account for a wide geographical spread. 
Additionally, since HPV testing is typically performed in conjunction with routine Papanicolaou 
(Pap) testing, and rates of routine testing are above 80% in U.S. women over 18 years of age, the 
data represent generalizable rates free from selection bias associated with testing typically 
performed to support clinical suspicion of disease [26]. 
Methods 
Study Population and Analysis Datasets 
This study was approved by an Institutional Review Board. Samples are submitted to and tested 
by a National Reference Laboratory for high-risk HPV (genotypes 16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 58, 59, and 68). Data from patient test results archived in an electronic data warehouse 
were extracted for HPV results from January 1, 2004 to June 1, 2013 to produce 757,761 female 
patient records with conclusive positive or negative results. Attached to each record were test 
results and demographic data including age, sex, and client information. Using only the first 
observation for each patient per calendar year between 2004 and 2013, a longitudinal dataset was 
created, consisting of 735,437 total high-risk HPV results from 590,036 unique patients at 692 
unique client sites in 48 U.S. states. 
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HPV testing 
Liquid-based endocervical samples were collected and submitted to the National Reference 
Laboratory for HPV testing. Acceptable sample types include Digene® Cervical Brushes 
(Qiagen, Hilden, Germany), ThinPrep® PreservCyt® media (Hologic, Inc., Marlborough, MA), 
and SurePath™ preservative (Becton-Dickinson, Franklin Lakes, NJ). Testing for HPV was 
performed according to manufacturer’s instructions by the Digene® hc2 HPV DNA Test, which 
utilized Hybrid Capture 2 technology. ThinPrep® PreservCyt® samples were prepared using the 
Digene® HC2 Sample Conversion Kit. 
Statistical analysis 
Positivity rates were analyzed by age category and year (both individual year and year 
categories: 2004-2007, 2007-2013) and compared. Frequency tables and exact binomial 
confidence intervals were constructed to present positivity rates (with 95% confidence intervals 
[CI]) by age category and year. Generalized linear models (GLM) were created to assess 
differences in positivity between age categories and assess changes over time [27]. Two- and 
three-way interaction models were used to assess both how rates have changed in the pre- and 
post-vaccine eras and also how age category affects this pre- and post-vaccine era effect on rate, 
respectively. 
To account for potential bias associated with differences in ordering, several methods were 
employed. First, it was hypothesized that a positive bias might be associated with physicians who 
submit specimens for HPV testing based on abnormal cytology results [28]. Therefore, finite 
mixture models were then used to investigate patterns within the distribution of time between 
sample collection and time of final result release for all patients (Figure 1) [29,30]. Positivity 
rates between these different testing patterns were compared. Additionally, sensitivity analyses 
were performed using GLM to assess the effects of time between visit, client size, and client 
consistency on positivity rates [27]. Time between visits was calculated for patients with more 
than one visit as the average time between visits. Client size was calculated as number of tests 
ordered overall and for each year. Client consistency was an indicator variable representing 
whether or not a client had ordered tests both at the beginning and end of the study period (tests 
ordered in 2004 and 2013). These derived variables were compared for both their main effect on 
positivity rate and interaction effects with time on positivity rates. 
All calculations were performed using SAS software (v9.3, SAS Institute Inc., Cary, NC, USA). 
Results were considered statistically significant if p<0.05. 
Results 
Raw Positivity Rates: High-risk HPV 
Positivity rates for high-risk HPV were separated and compared across time and by age groups 
(Table 1). 















Overall 256,683 19.4 51,080 31.6 119,896 18.6 85,707 13.2 
14-19 10,979 50.6 4,692 55.5 5,224 47.8 1,063 43.0 
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20-24 25,725 50.2 9,276 54.1 11,525 49.5 4,924 44.4 
25-29 24,363 36.8 7,545 41.2 11,219 36.8 5,599 30.8 
30-39 77,928 15.7 12,439 24.4 36,104 15.1 29,385 12.7 
40-49 67,841 9.5 10,824 14.7 31,955 9.0 25,062 8.0 
50-59 49,847 7.4 6,304 12.4 23,869 7.1 19,674 6.2 
Table 1. Positivity of High-risk HPV According to Age and Year Group in Pattern 1 Individuals 
from a National Reference Laboratory. 
Overall the positivity rate in women aged 14 to 59 years from 2004 to 2013 (n=735,437) was 
27.2% (95% confidence interval [CI], 27.1 to 27.3). When separated by time period, the 
positivity rates decreased over time, with the pre-vaccine introduction period (2004 to 2006) 
having an overall positivity rate of 35.3% (95% CI, 35.1 to 35.5) and the final time period (2011 
to 2013) having an overall positivity rate of 19.7% (95% CI, 19.5 to 19.9). 
When separated by age group, each showed a significant decline in overall positivity over time. 
The largest absolute decrease was in the 30 to 39 year old age group, with a decrease from 27.2% 
(95% CI, 26.7 to 27.6), in the years 2004 to 2006, to 16.3% (95% CI, 16.1 to 16.6), in the years 
2011 to 2013. The smallest absolute decrease was in the 25 to 29 year old age group, with a 
decrease from 44.0% (95% CI, 43.4 to 44.6), in the years 2004 to 2006, to 42.7% (95% CI, 41.9 
to 43.4), in the years 2011 to 2013 (Table 1). Overall, current rates were highest in both the 14 to 
19 year old and 20 to 24 year old age categories, with the positivity rate being 54.5% (95% CI, 
52.9 to 56.2), and 54.7% (95% CI, 54.0 to 55.5), respectively in the years 2011 to 2013. 
Factors and Significance of Bias 
To establish if physician ordering practices influenced positivity, it needed to be determined if an 
indication for ordering HPV testing was present prior to sample submission. This was 
accomplished by analysis of the difference in collection time (reported by the client) and the 
result time (time at which results are reported from the National Reference Laboratory). Finite 
mixture models were used and established two distinct populations of patient samples submitted; 
a population with a peak resulting time minus collection time at three days, and another at eight 
days (Figure 1). 
A nadir (antimode) in the mixture model was observed at five days, which was then used as the 
cutoff between pattern 1 datasets (<5 days) and pattern 2 datasets (>5 days). This is consistent 
with previous studies conducted at the National Reference Laboratory and matches data that the 
majority of cytological results on Pap specimens are completed within five days [28,31]. We also 
examined the subset of cases with both HPV test and Pap smear results to validate our 
assumption that HPV testing delayed beyond five days was likely the result of abnormal 
cytology results. This subset (n = 9,347) showed a bimodal peak, with normal cytology results 
associated with HPV test results on average six days later, whereas abnormal cytology results 
had HPV results reported on average eight days later. Therefore, it is hypothesized that samples 
in the pattern 2 dataset were submitted with suspicion of HPV as a result of abnormal cytological 
findings and should be excluded from our estimates of HPV prevalence. Positivity rates support 
this, as they are significantly higher in pattern 2 compared to pattern 1 in all age groups across all 
years (Tables 1, 2). Additionally, sensitivity analyses performed using general linear models 
showed no statistically significant effect of time between visit, client size, and client ordering 
consistency on positivity rates. 
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Figure 1: Finite Mixture Modeling (FMM) of time between collection and final result indicating 
distinct distributions. 
 
 Rate of positive change per year, %  
Age, 
years 
2004-2006 2007-2013 Difference 
14-19 -2.2 -1.5 0.7 
20-24 -0.1 -1.5 -1.4* 
25-29 0.4 -1.5 -1.9* 
30-39 -3.0 -0.8 2.2* 
40-49 -1.7 -0.4 1.3* 
50-59 -1.4 -0.3 1.1* 




Trends: High-risk HPV 
Following investigation of potential influences on the positivity rate and determining if they had 
significance or not, it was estimated that the positivity rates in pattern 1 should provide a useful 
indicator of underlying population prevalence of sexually active women getting regular 
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gynecological screening. Overall positivity in this pattern 1 group of high-risk HPV for women 
aged 14 to 59 years from 2004 to 2013 was 19.4% (95% CI, 19.3 to 19.6). Over time, the 
positivity rates decreased from 31.6% (95% CI, 31.2 to 32.0) during the years 2004 to 2006, to 
13.2% (95% CI, 13.0 to 13.4) during the years 2011 to 2013. 
Women aged 14 to 19 years showed the largest absolute decrease in the pattern 1 group in 
positivity from 55.5% (95% CI, 54.0 to 56.9) during the years 2004 to 2006, to 43.0% (95% CI, 
40.0 to 45.9) during the years 2011 to 2013. Women aged 50 to 59 showed the largest percent 
decrease, dropping 49.7% in prevalence from 12.4% (95% CI, 11.6 to 13.2) during the years 
2004 to 2006, to 6.2% (95% CI, 5.9 to 6.6) during the years 2011 to 2013. The smallest percent 
decrease was seen in women aged 20 to 24, with only an 18.0% reduction in positivity from 
54.1% (95% CI, 53.1 to 55.1) during the years 2004 to 2006, to 44.4% (95% CI, 43.0 to 45.8) 
during the years 2011 to 2013. 
Rates of change in high-risk HPV positivity per year were calculated and compared between the 
pre-vaccination (2004-2006) and post-vaccination periods (2007-2013) in all age groups. 
Generalized linear models showed that age category had a significant effect on rates when these 
time periods were compared. In the pattern 1 group, all age categories showed positivity 
decreases in the post-vaccine period; however, only women aged 20 to 24 and 25 to 29 showed 
negative differences (-1.4% per year and -1.9% per year, respectively) when pre- and post-
vaccine period rates of change were compared. All other age categories had rates of change that 
were less negative, and closer to zero (Figure 2, Table 2). 
Discussion 
The goal of this study was to establish and evaluate a tool to estimate the current positivity of 
and trends in high-risk HPV in women in the United States from 2004 to 2013; specifically, in 
women who undergo regular gynecological screenings. These data indicate that the overall 
positivity of HPV is declining, especially in young women; however, the rate at which positivity 
is declining is slower than other studies indicate in certain age categories [17]. This may be a 
combination of insufficient vaccination coverage as well as these data being a mixture of 
vaccine-preventable and other high-risk types collectively. Mathematical models have predicted 
that the introduction of the vaccine should have a strong impact on HPV positivity rates in the 
types covered by the vaccine [14]. While this data could not be separated entirely by type, a 
reduction of 18 to 25% in positivity in all high-risk HPV was seen in women aged 14 to 29 when 
comparing rates prior to the vaccine introduction (2004 to 2006) to current rates (2011 to 2013). 
While most studies performed to determine HPV positivity or prevalence rely on survey-based 
methods, this study has several strengths that allow for the generalizability of the results to 
women who undergo regular gynecological screening in the US. First, the data were 
retrospective data from a large national reference laboratory, which created a large dataset of 
more than 700,000 high-risk HPV results that accurately reflected at-risk and vaccine-targeted 
population. Second, the data were filtered in several ways: only the first visit per calendar year of 
each patient was used to reduce redundancy that may occur as a result of repeat confirmatory 
testing, and potential ordering bias was reduced by separating results from patient samples 
believed to be submitted because of abnormal cytology results. To account for ordering bias, 
finite mixture modeling was used to determine where, if any, a separation may exist between the 
time the samples were collected and the time that results were entered [29]. The separation 
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observed is likely the result of samples being immediately sent for HPV testing versus samples 
that had been  
 
 
Figure 2: High-risk HPV positivity in pattern 1 individuals by year and age category from a 
National Reference Laboratory. 
 
screened for abnormal cytology before being sent for HPV testing [28]. The cutoff between 
pattern 1 and 2 of five days can be further supported by a 2013 survey by the College of 
American Pathologists (CAP) that showed that 83.9% of Papanicolaou testing took less than five 
days to completion, with the majority taking 3 to 4 days [31]. Additionally, the positivity rates in 
testing pattern 2 were significantly higher than in testing pattern 1, suggesting physicians had an 
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indication for ordering HPV testing, such as abnormal Pap smear results. Lastly, sensitivity 
analyses were performed to determine if differences in clients might influence the positivity 
rates. Since these data included many individual client sites, it was theorized that differences in 
client size might account for a bias in positivity: clients with fewer sample submissions may be 
targeting at-risk individuals with a higher likelihood of disease. Using generalized linear models, 
it was shown that there were no differences in positivity rates when adjusting for client size, 
location, or ordering trends, further supporting that the positivity rates truly are indicative of 
overall prevalence. 
Based on retrospective data from a national reference lab from 2004 to 2013, the overall 
positivity of high-risk HPV in all age groups was 27.2%. Looking at only pattern 1, which was 
established as an estimate of unbiased prevalence, the rate drops to 19.4%. Our estimate of pre-
vaccine high-risk HPV positivity in women 14 to 59 years old was 31.6%, compared to the rates 
reported from other studies of 15 – 29% [16,17]. For the current time period (2010-2013), the 
positivity rate decreases to 13.2% for all women aged 14 to 59. By age group, our positivity 
estimates are also higher, particularly in the 14-19 year old group (55-57%) when compared to 
CDC data (15-20%). This could be due to the fact that HPV testing is generally only performed 
for sexually active women; so positivity estimates in this study likely reflect the positivity rates 
in the sexually active population, which has been shown to be close to 50% in young adult 
females, similar to the present study [16,17]. Furthermore, the method of specimen collection 
differed from other studies in that provider-collected cervical swabs were used as opposed to 
self-collected cervicovaginal swabs. Provider collection could not feasibly be standardized in this 
study, but overall performance of HPV testing has been shown to be similar for both collection 
methods [32]. 
It is important to note that despite a decline in high-risk HPV positivity in all age categories, the 
rate of positivity change per year is not consistent. HPV vaccination is only recommended in 
women up to the age of 26; therefore, this group would likely have a faster decrease in positivity. 
It could further be postulated that, since the vaccinated population is increasing in age, an inverse 
relationship between age and change in prevalence per year would exist. This was observed, with 
the post-vaccine introduction period rates of positivity change per year being consistent in the 
vaccine target group (age groups 14 to 19, 20 to 24, and 25 to 29) at a -1.5% and decreasing with 
each increase in age category to a low of -0.3% in the 50 to 59 year old group. The decreasing 
rates that were seen in the pre-vaccine introduction period are likely due to inconsistent testing 
practices among physicians and an increasingly heterogeneous population being screened; 
however, these rates still provide a baseline to compare post-vaccine period rates. Crucially, the 
difference in the pre- and post-vaccine era rates of positivity change were only more negative in 
the age groups that had overlap in vaccine and screening guidelines (20 to 24 and 25 to 29-year-
old women). This suggests that the decreases in the rates of prevalence change per year seen in 
the younger population age categories could be due to increasing vaccination rates. 
For comparison, 618,261 Chlamydia tests were analyzed for females stratified by the same age 
categories as for HPV and covering years 2004-2013 (Supplemental online figure). Across all 
age categories, there is no significant downward trend in positivity rates and, in fact, most age 
categories show an upward trend (especially since 2008). These results further support the 
hypothesis that downward trends observed in HPV are likely attributable to vaccine uptake. 
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Limitations of Study 
Several limitations to this study exist. Current guidelines recommend screening every three years 
in all sexually active women over 21 years of age; therefore, and as a result of the data being 
collected at a national reference lab, the population represented is likely a sexually active 
population with access to healthcare. Furthermore, cervical cancer screening guidelines have 
changed over the duration of data collection, with the introduction of co-testing HPV and Pap 
screening in women older than 30 years and recommendation against screening in women less 
than 21 years regardless of first sexual contact [33,34]. Despite these changes, these data and 
several studies indicate that the guidelines are not being followed as testing is still frequently 
performed on an annual basis, in women under 21 years of age, and in women following 
hysterectomy [28,35,36]. Another final limitation is that the Hybrid Capture 2 method does not 
differentiate genotypes and differentiation of specific high-risk vaccine preventable HPV strain 
was not possible [37,38]. 
We attempted to mitigate some of the potential biases by focusing on collection pattern 1 (results 
within five days of collection) and only including one visit within the calendar year, but future 
studies of this kind will certainly be needed to both validate and improve upon methodology. 
Additional studies that have access to multiple testing sites may be able to refine analyses by 
using characteristics of the different client sites: for example, differences in ordering volumes, 
within-center positivity rates, or information collected outside of the analytic framework, such as 
clinical indications for testing in their population. Our study demonstrates the potential for using 
HPV test data from large national reference laboratories to supplement the ongoing and planned 
efforts to monitor HPV vaccine impact in the US [39]. 
Conclusion 
In evaluating the surveillance tool, we find that it is important to consider many sources of 
heterogeneity, e.g., age, type of test, location, and type of testing center, and also consider 
quantitative methods of adjustment and distribution assessment to construct a useful surveillance 
tool. Further studies should expand on this methodology. 
The results of the surveillance tool indicate a downward trend in vaccine-appropriate age groups 
consistent with uptake of the HPV vaccine. The pre-post rate changes were in direct contrast 
between the age-appropriate groups and the groups too old for the HPV vaccine, further 
indicating the surveillance tool may be detecting the impact of the HPV vaccine over time. After 
refinement, this surveillance tool should remain in place to observe the future impact of the HPV 
vaccine. 
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Supplemental figure: Comparison of positivity rates between high-risk HPV (pattern 1 
individuals) and Chlamydia by year and age category from a National Reference Laboratory. 
